Clinical Study of The Novel Antiseptic Olanexidine Gluconate in Gastrointestinal Cancer Surgery
Abstract Background Surgical site infection (SSI) is a common complication of digestive surgery .Olanexidine gluconate (OLG) is a novel developed skin antiseptic and effective against a wide range of bacteria. The purpose of this study is to evaluate the bactericidal efficacy of OLG in gastrointestinal cancer surgery. Methods This retrospective study included a total of 281patients who underwent gastrointestinal cancer surgery (stomach or colon). There were two group: 223 patients were treated with OLG (OLG group), and 58 patients were treated with povidone-iodine (PVP-I) (control group). The efficacy and the safety outcomes were measured as the rate of surgical SSI within 30 days after surgery. In addition, we also conducted subgroups defined according to the surgical approach (open or laparoscopic) or primary lesion (stomach or colon). Results There was a significant difference in the rate of SSI between the control group and OLG group (10.3% vs. 2.7% ; p = 0.02). There was a significant difference in the SSI rate in superficial infection (8.6% vs. 2.2% ; p = 0.0345) but not in deep infection (1.7% vs. 0.5% ; p = 0.371). There was no significant difference between the control group and OLG group in the overall rate of adverse skin reaction (5.2% vs. 1.8% ; p = 0.157). Conclusion This retrospective study demonstrates that OLG is more effective than PVP-I for preventing SSI during gastrointestinal cancer surgery.